TransMedics Group (NASDAQ:TMDX – Get Free Report) had its target price raised by stock analysts at Stifel Nicolaus from $70.00 to $80.00 in a report issued on Friday, Benzinga reports. The brokerage presently has a “hold” rating on the stock. Stifel Nicolaus‘s target price points to a potential downside of 14.91% from the stock’s previous close.
Several other equities research analysts have also recently weighed in on TMDX. Canaccord Genuity Group upped their target price on TransMedics Group from $95.00 to $120.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Weiss Ratings upgraded TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. TD Cowen reissued a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a report on Tuesday, September 8th. Barclays assumed coverage on TransMedics Group in a report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price target for the company. Finally, UBS Group upped their price objective on TransMedics Group from $77.00 to $88.00 and gave the stock a “neutral” rating in a research report on Monday, November 9th. Five investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, TransMedics Group has an average rating of “Hold” and a consensus target price of $113.30.
View Our Latest Research Report on TMDX
TransMedics Group Price Performance
TMDX stock opened at $94.02 on Friday. The company has a quick ratio of 4.15, a current ratio of 4.53 and a debt-to-equity ratio of 1.46. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00. The firm has a market cap of $3.27 billion, a P/E ratio of 52.98, a P/E/G ratio of 1.71 and a beta of 2.14. The company’s 50-day moving average price is $80.82 and its two-hundred day moving average price is $91.19.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.30 by $0.21. The company had revenue of $203.01 million during the quarter, compared to analysts’ expectations of $178.06 million. TransMedics Group had a net margin of 19.85% and a return on equity of 13.30%. The business’s revenue for the quarter was up 41.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.66 EPS. On average, analysts anticipate that TransMedics Group will post 1.66 earnings per share for the current fiscal year.
Insider Transactions at TransMedics Group
In related news, Director David Weill acquired 1,336 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was acquired at an average price of $81.63 per share, with a total value of $109,057.68. Following the purchase, the director directly owned 16,392 shares in the company, valued at approximately $1,338,078.96. This trade represents a 8.87% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. Advisors Asset Management Inc. acquired a new stake in shares of TransMedics Group during the 3rd quarter valued at $248,000. Allworth Financial LP increased its holdings in TransMedics Group by 32.4% in the 3rd quarter. Allworth Financial LP now owns 3,336 shares of the company’s stock worth $278,000 after purchasing an additional 816 shares in the last quarter. Portolan Capital Management LLC increased its holdings in TransMedics Group by 102.6% in the 3rd quarter. Portolan Capital Management LLC now owns 166,828 shares of the company’s stock worth $13,922,000 after purchasing an additional 84,474 shares in the last quarter. Aquatic Capital Management LLC bought a new position in TransMedics Group in the third quarter valued at about $1,270,000. Finally, Toronto Dominion Bank bought a new position in TransMedics Group in the third quarter valued at about $6,595,000. 99.67% of the stock is currently owned by institutional investors.
About TransMedics Group
TransMedics Group, Inc. is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services. The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.
See Also
- Five stocks we like better than TransMedics Group
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
